Key result
Reactogenicity after a heterologous mRNA-1273 booster was similar to a homologous booster (88.0% vs. 90.2%, p=0.3), though homologous boosters were associated with more medical leave (AOR 1.45).
Why the study?
The study assessed local and systemic adverse reactions after an mRNA-1273 booster according to the primary series vaccine type and homologous versus heterologous boosting in health care workers.
Does a heterologous mRNA-1273 booster cause different reactogenicity compared to a homologous booster in health care workers?
Cross-Sectional
No
Does a heterologous mRNA-1273 booster cause different reactogenicity compared to a homologous booster in health care workers?
Absolute Event Rate: 88% vs 90.2%
p-value: p=0.3
Heterologous mRNA-1273 booster vaccination has a similar reactogenicity profile to homologous boosting, supporting its safety and use in the general population.
Heterologous mRNA-1273 boosting may be tolerable in HCW; leaves open generalizability and causality in broader populations.
The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). A cross-sectional study was performed in HCW at a tertiary hospital in Barcelona, Spain. A total of 17% of booster recipients responded to the questionnaire. The frequency of reactogenicity after the mRNA-1273 booster (88.5%) was similar to the mRNA-1273 primary doses (85.8%), and higher than the BNT162b2 primary doses (71.1%). The reactogenicity was similar after receiving a heterologous booster compared to a homologous booster (88.0% vs. 90.2%, p = 0.3), and no statistically significant differences were identified in any local or systemic reactions. A higher frequency of medical leave was identified in the homologous booster dose group vs. the heterologous booster dose group (AOR 1.45; 95% CI: 1.00–2.07; p = 0.045). Our findings could be helpful in improving vaccine confidence toward heterologous combinations in the general population and in health care workers.
No takes yet. Share an insight, caveat, or question.
Parés‐Badell et al. (2022) conducted a cross-sectional in COVID-19 vaccination. Heterologous mRNA-1273 booster vs. Homologous mRNA-1273 booster was evaluated on Reactogenicity (local and systemic adverse reactions) (p=0.3). Reactogenicity after a heterologous mRNA-1273 booster was similar to a homologous booster (88.0% vs. 90.2%, p=0.3), though homologous boosters were associated with more medical leave (AOR 1.45).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: